Generated second quarter revenue of $14.5 million, an increase of approximately 120% year-over-year Raising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million,...
GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people...
The new app will offer an enhanced user experience and exciting new features, including improved integration popular digital health tools The app is expected to launch in the second half of 2026 ...
The new app will offer an enhanced user experience and exciting new features, including improved integration popular digital health tools The app is...
Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and...
Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance New data expands on findings...
GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development,...
GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term,...
Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) raised its full-year 2026 revenue outlook after reporting first-quarter growth tied to adoption of its Eversense 365 continuous glucose monitoring system...